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Abstract
Background: Ovarian cancer is the most fatal gynecologic malignancies in the world. Although, platinum based
treatments are widely used, the disease becomes treatment refractory within two years, and novel treatment
options should be searched. All- trans retinoic acid (ATRA) induces growth arrest, differentiation and cell death in
some types of cancer cells and its combination with various anticancer agents results in enhanced cytotoxicity.
Zoledronic acid is a common bisphosphonate known for its anticancer effects beyond its current use in the
treatment of cancer-induced bone disease. We aimed to investigate the possible additive/synergistic effect of both
agents in OVCAR-3 and MDAH-2774 ovarian cancer cell lines, since both agents show superiority to conventional
cytotoxics in terms of adverse events.
Methods: XTT cell proliferation assay was used for showing cytotoxicity. For verifying apoptosis, both DNA
Fragmentation by ELISA assay and caspase 3/7 activity measurement were used. OligoGeArray® which consists of
112 apoptosis related genes was used to elucidate the genetic changes within cancer cells. To validate our
oligoarray results, quantitative real-time PCR was performed on four selected genes that were maximally effected
by the combination treatment: lymphotoxin beta receptor (LTBR), myeloid cell leukemia-1 (MCL-1), tumor necrosis
factor receptor superfamily, member 1A (TNFRSF1A), TNFRSF1A-associated death domain protein (TRADD).
Results: We demonstrated that a novel combination of ATRA and zoledronic acid is a strong inducer of apoptotic
related cell death in both ovarian cancer cells. While the combination therapy significantly induced proapoptotic
genes such as tumor necrosis factor receptor superfamily (TNFRSF), TRADD and caspase 4, some of the
antiapoptotic genes such as members of MCL-1, LTBR, BAG3 and Bcl-2 family members were inhibited.
Conclusions: These are the preliminary molecular results of a novel combination treatment of ATRA and
zoledronic acid, with fewer side effects as compared to conventional cytotoxic agents. With additional
experimental analysis, it may serve as a good option for the treatment of refractory and elderly ovarian cancer
patients, for whom there exists very limited choice of treatment.
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Ovarian cancer is the most fatal gynecologic malignancy
in the world [1]. Standard chemotherapy for previously
untreated patients with advanced ovarian cancer consists
o ft h ec o m b i n a t i o no fat a x a n ea n dap l a t i n u mc o m -
pound. However, the disease becomes chemo-refractory
within approximately two-years, and second-line treat-
ment options do not provide significant survival advan-
tage [2]. Thus, novel treatment approaches are needed
to be investigated for this era.
Retinoids include both natural and synthetic deriva-
tives of vitamin A. In the cell, they act by binding
nuclear receptors that function as retinoid-dependent
transcriptional factors, including the RAR and RXR
receptors [3,4]. All- trans retinoic acid (ATRA), a nat-
ural derivative of vitamin A, induces growth arrest, dif-
ferentiation and cell death of different types of cancer
cell lines in vitro [5,6]. In the literature, there is a body
of evidence that ATRA enhances the cytotoxic effects of
chemotherapeutic agents [7-10]. There are some
encouraging data from preclinical trials that have
demonstrated the efficacy of using retinoids and cyto-
toxics in combination [11-13].
Zoledronic acid, a third-generation bisphosphonate,
inhibits osteoclastic resorptive activity partly through
inhibition of farnesyl-diphosphate synthase and protein
prenylation [14]. Though it is mainly used for the treat-
ment of cancer-induced bone disease, the promising
findings coming from substantial amount of preclinical
and early clinical evidence on the cytotoxic effect of
zoledronic acid have led to several ongoing studies that
will ascertain the benefit of zoledronic acid, itself, may
act as a new antitumor agent in some human cancers
[14,15]. Latest trials have demonstrated that zoledronic
acid also has diverse anti-tumor effects via multiple
mechanisms [16,17]. In preclinical models, bisphospho-
nates directly inhibit tumour growth and angiogenesis.
Two recent clinical trials, ABCSG13 and Z/Zo-FAST
have shown a disease-free survival benefit with zoledro-
nic acid in women receiving adjuvant endocrine therapy
[18,19]. Thus, it has been discussed to be used in the
extended adjuvant treatment of early breast cancer as a
new, promising anti cancer drug.
The wide spectrum toxic side effects of cytotoxic treat-
ment as well as drug resistance occur to be important
limitations of management of ovarian cancer, thus new
treatment approaches are needed. Based on the knowl-
edge of ATRA may work as enhancer of cytotoxic effect
when added to other drugs, we investigated the possible
additive/synergistic combination of ATRA with zoledro-
nic acid in human ovarian cancer cell lines, OVCAR-3
and MDAH-2774. Since both of the agents have much
more tolerable side effects as compared to conventional
cytotoxic drugs, we searched for if this new combination
might be a hope for elderly ovarian cancer patients.
Ovarian cancer cell lines can potentially overcome the
experimental limitations inherent in both the animal
models of ovarian cancer and the primary cloning of
human ovarian cancer specimens. The availability of
adequate quantities of proliferating cancer cells would
also facilitate the identification of potentially clinically
useful dose-response relationships with anti-cancer
drugs as well as a model system in which to compare
the cytotoxicity of drug analogues. OVCAR-3 is a highly
metastatic, drug resistant human ovarian carcinoma cell
line, and thus it is an ideal model to study the effects
and mechanisms of various anticancer agents [20].
Besides, MDAH-2774 represents an example of slow-
growing tumor type and was chosen a reciprocal experi-
mental effect when used with OVCAR-3.
Methods
Cell lines and reagents
Human ovarian OVCAR-3 and MDAH-2774 cancer
cells were obtained from ICLC (Genova, Italy). The cells
were grown as monolayers in adherent cell lines and
were routinely cultured in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 1%
L-glutamine, 1% penicillin-streptomycin in 75 cm
2 poly-
styrene flasks (Corning Life Sciences, UK) and main-
tained at 37°C in a humidified atmosphere with 5%
CO2. Cell culture supplies were obtained from Biological
Industries (Kibbutz Beit Haemek, Israel). ATRA was
obtained from Sigma Chemical Co (USA). Zoledronic
acid was a generous gift from Novartis Pharmaceuticals
Inc. (Basel, Switzerland). The stock solution of ATRA
was prepared in DMSO (43 mM) and, zoledronic acid
(10 mM) was prepared in distilled water. The DMSO
concentration in the assay did not exceed 0.1% and was
not cytotoxic to the tumor cells. All other chemicals,
unless mentioned, were purchased from Sigma.
XTT cell viability assay
After verifying cell viability using trypan blue dye exclu-
sion test by Cellometer automatic cell counter (Nexce-
lom Inc., USA.), cells were seeded at approximately
1×10
4/well in a final volume of 200 μl in 96-well flat-
bottom microtiter plates with or without various con-
centrations of drugs. Plates were incubated at 37°C in a
5% CO2 incubator for the indicated time periods. At the
end of incubation, 100 μl of XTT (2,3-bis (2-methoxy-4-
nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-
tetrazolium hydroxide) (Roche Applied Science,
Mannheim, Germany) was added to each well, and
plates were incubated at 37°C for another 4 hours.
Absorbance was measured at 450 nm against a reference
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man Coulter, DTX 880 Multimode Reader). The mean
of triplicate experiments for each dose was used to cal-
culate the IC50 and the combination index (CI) values.
Evaluation of apoptosis
Apoptosis was evaluated by enzyme-linked immunosor-
bent assay (ELISA) using Cell Death Detection ELISA
Plus Kit (Roche Applied Science, Mannheim, Germany)
and verified by measuring caspase 3/7 enzyme activity
(Caspase-Glo 3/7 Assay, Promega, Madison, WI). Assays
were described in our previous study [21].
Examination of the expression levels of apoptotic genes
by oligoarray method
Expression levels of apoptosis specific genes were exam-
ined by Human Apoptosis OligoGEArray® (SuperArray,
Frederick, MD). The OligoGEArray Human Apoptosis
microarray profiles the expression of 112 genes involved
in apoptosis. This array includes tumor necrosis factor
(TNF) ligands and their receptors, members of the bcl-2
gene family, caspases and some other important apopto-
sis-related genes. Briefly, total RNA was extracted from
cell samples using an Array Grade Total RNA isolation
kit (SuperArray, Frederick, MD) and quantitated by UV
spectroscopy using a biophotometer. The integrity and
quality of isolated RNA was determined by running the
RNAs on agarose gel electrophoresis. cDNA was labeled
from total RNA with Biotin 16-dUTP and the GEArray®
TM Amp Labeling-LPR Kit (SuperArray, Frederick,
MD) according to manufacturer’s instructions. The bio-
tin-labeled cDNA was than added to the membrane and
hybridized overnight to Human Apoptosis OligoGEAr-
ray® as stated by the manufacturer. Signal detection was
achieved by exposure to CDP-Star alkaline phosphatase
chemiluminescent substrate (SuperArray, Frederick,
MD). An image was processed using Kodak® Gel Logic
1500 Imaging System and analyzed with the GEArray
Analyzer Software. Experiments were repeated thrice
using RNA extracted from three different cultures.
Real time quantitative RT-PCR (qRT-PCR) assay
To validate our oligoarray results, quantitative real-time
PCR was performed on four selected genes that were
maximally effected by the combination treatment: lym-
photoxin beta receptor (LTBR), myeloid cell leukemia-1
(MCL-1), tumor necrosis factor receptor superfamily,
member 1A (TNFRSF1A), TNFRSF1A-associated death
domain protein (TRADD). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a positive control
by using Real-Time™ qPCR Primer Assay (SABioscience,
Frederick, MD) on Light Cycler 480 instrument (Roche
Applied Science, Mannheim, Germany). Total RNA of
4 μg was extracted from cell samples using an Array
Grade Total RNA isolation kit (SuperArray, Frederick,
MD) and quantitated by UV spectroscopy using a bio-
photometer. The integrity and quality of isolated RNA
was determined by running the RNAs on agarose gel
electrophoresis. PCR reaction mix was prepared 25 μl
final volume containing 12,5 μl RT2 SYBR Green qPCR
Master Mix, 10,5 μl DNAase-RNaseFree water, 1,0 μl
gene-specific 10 μM PCR primer pair stock and finally
1,0 μl diluted cDNA samples for each primer
(SABioscience). Universal cycling conditions (10 min at
95°C, 15 s at 95°C, 1 min 60°C for 40 cycles) were car-
ried out. The melting protocol consisted of 95°C for
1 minutes and a continuous fluorescense reading from
65°C to 95°C at 30 acquisitions per degree and 1°C ris-
ing per second. Data normalization and analysis an
endogenous control, GAPDH present on the PCR was
used for normalization. Each replicate cycle threshold
(CT) was normalized to the average CT of endogenous
control on a sample basis. The comparative CT method
was used to calculate the relative quantification of gene
expression. The following formula was used to calculate
the relative amount of the transcripts in the drugs trea-
ted samples and the control group, both of which were
normalized to the endogenous control. ΔΔCT = ΔCT
(drugs treated) - ΔCT (control) for RNA samples. ΔCT
is the log
2 difference in CT between the target gene and
endogenous controls by subtracting the average CT of
controls from each replicate. The fold change for each
treated sample relative to the control sample = 2
-ΔΔCT.
Statistical analysis
All experiments were conducted in triplicate and the
results expressed as the mean ± (sd), with differences
assessed statistically p values determined by Student’s t-
test. p < 0.05 was accepted as significant. Median dose
effect analysis, a measure of synergism or antagonism,
was determined by the method of Chou and Talalay,
using their computer program (Biosoft CalcuSyn, Fer-
guson, MO, USA) to assess drug interaction. We chose
this method because it takes into account both the
potency of each drug or combination of drugs and the
shape of dose-effect curve. CalcuSyn software which is
based on this method was used to calculate the CI.
Synergy, additivity and antagonism were defined as CI
< 1, CI = 1, CI > 1, respectively, where CI ≤ 0.5 char-
acterizes strong synergy. For this analysis, concentrations
of ATRA and zoledronic acid were chosen as clinically
achievable concentrations and below the IC50 values [22].
Results
Effect of either single ATRA or zoledronic acid on the
viability of OVCAR-3 and MDAH-2774 cells
To evaluate the effects of ATRA on the viability
of human ovarian cancer cells, OVCAR-3 and
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trations of ATRA (40 to 140 nM) for 24, 48 and 72 h,
and XTT cell viability assay was performed. ATRA
decreased cell viability in a time- and dose dependent
manner both in OVCAR-3 and MDAH-2774 cells (data
not shown). As shown in figure 1, there were 20-, 41-,
and 73% decrease in cell viability of OVCAR-3 cells
e x p o s e dt o4 0 - ,1 0 0 - ,a n d1 2 0n Mo fA T R A ,r e s p e c -
tively, when compared to untreated controls at 72 h (p
< 0.05). In addition, there were there were 28-, 49.5-,
and 58% decrease in cell viability of MDAH-2774 cells
e x p o s e dt o4 0 - ,1 0 0 - ,a n d1 2 0n Mo fA T R A ,r e s p e c -
tively, when compared to untreated controls at 72 h (fig-
ure 1) (p < 0.05). Highest cytotoxicity was observed at
72 h and IC50 values of ATRA were calculated from cell
proliferation plots and found to be 85 and 82 nM in
OVCAR-3 and MDAH-2774 cells, respectively.
We also examined the effect of zoledronic acid on
OVCAR-3 and MDAH-2774 cells. Cells were exposed to
increasing concentrations of zoledronic acid (2.5- to 40
μM) for 24, 48 and 72 h. There were 18-, 26-, and 60%
decreases in cell viability of OVCAR-3 cells exposed to
5 - ,1 0 - ,a n d2 0μM of zoledronic acid, respectively,
when compared to untreated controls at 72 h (figure 2)
(p < 0.05). In MDAH-2774 cells, there were 22-, 35-,
and 65% decreases in cell viability of MDAH-2774 cells
exposed to 5-, 10-, and 20 μM of zoledronic acid,
respectively (figure 2) (p < 0.05). Highest cytotoxicity
was observed at 72 h and IC50 values of zoledronic acid
in OVCAR-3 and MDAH-2774 cells were calculated
from cell proliferation plots and were found to be 15.5
and 13 μM, respectively.
ATRA and zoledronic acid combination treatment in
OVCAR-3 and MDAH-2774 cells
To study the possible synergistic/additive effects of
ATRA and zoledronic acid combination, OVCAR-3 and
MDAH-2774 cells were exposed to different concentra-
tions of each agent alone, and in combination of both
for 24, 48 and 72 hours. The synergism or additivity was
calculated via CI by using Biosoft Calcusyn Program.
Combination of different concentrations of ATRA and
zoledronic acid were evaluated at different time points
(data not shown). Results showed synergistic toxicity in
both ovarian cancer cells, OVCAR-3 and MDAH-2774,
at 72 h, as compared to any agent alone as shown in
table 1. Our results indicate that 80 nM ATRA and
5 μM zoledronic acid show 32%- and 18% decrease,
respectively, in cell viability of OVCAR-3 cells but the
combination of both resulted in 78% decrease in cell
viability (figure 3). In MDAH-2774 cells, 40 nM ATRA
and 5 μM zoledronic acid show 28%- and 22% decrease,
respectively, in cell viability of MDAH-2774 cells but
Figure 1 Effect of ATRA on viability of OVCAR-3 and MDAH-
2774 cells at 72 h in culture. The data represent the mean of
three different experiments (p < 0.05).
Figure 2 Effect of zoledronic acid (ZA) on viability of OVCAR-3
and MDAH-2774 cells at 72 h in culture. The data represent the
mean of three different experiments (p < 0.05).
Table 1 Combination index values
OVCAR-3
Concentration of Drugs CI value Interpretation
Zoledronic acid (5 μM) + ATRA (80 nM) 0.688 Synergism
Zoledronic acid (10 μM) + ATRA (80 nM) 0.705 Synergism
MDAH-2774
Concentration of Drugs CI value Interpretation
Zoledronic acid (5 μM) + ATRA (40 nM) 0.010 Synergism
Zoledronic acid (5 μM) + ATRA (80 nM) 0.009 Synergism
Combination index values of ATRA and zoledronic acid alone and in
combination in OVCAR-3 and MDAH-2774 cells. CI values were calculated from
the XTT cell viability assays. The data represent the mean of three
independent experiments
CI
a: Combination index
ATRA*: All trans retinoic acid
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viability (figure 3).
The concentrations for each agent found to be syner-
gistic in OVCAR-3 and MDAH-2774 cells are presented
in table 1.
Effects of the sequential treatment
The previous findings demonstrated that tumor cells
with ATRA and zoledronic acid resulted in significant
synergism at 72 h. Sequential administration of the
drugs were carried out to see if either of these drugs
enhance the other one’s effect and to understand
whether the synergism depended on which agent
applied first. We examined the effect of sequential treat-
m e n to fO V C A R - 3a n dM D A H - 2 7 7 4c e l l sw i t he i t h e r
ATRA or zoledronic acid and subsequent treatment
with the second agent. Pretreatment of tumor cells with
ATRA for 36 h and wash and then treatment for an
additional 36 h with zoledronic acid resulted in synergis-
tic cytotoxicity in OVCAR-3 and MDAH-2774 cells.
Also, pretreatment of tumor cells with zoledronic acid
for 36 h and wash and then treatment for an additional
3 6hw i t hA T R Ar e s u l t e di ns y n ergistic cytotoxicity in
OVCAR-3 and MDAH-2774 cells (data not shown). So,
synergistic cytotoxicity was observed no matter which
agent applied first in both cells.
Combination treatment induced apoptosis in a synergistic
manner
a) DNA Fragmentation
To examine the induction of apoptosis in response to
ATRA or zoledronic acid and combination of both in
ovarian cancer cells, we incubated these cells in the
presence of the agents alone or in combination of both
for 72 hours and then we quantified the levels of mono-
oligo nucleosome fragments by Cell Death Detection Kit
(Roche Applied Science, Mannheim, Germany). Our
results clearly showed that both ATRA and zoledronic
acid alone induced apoptosis in a dose-dependent man-
ner but the exposure to combination of both agents
resulted in synergistic induction of apoptosis by DNA
fragmentation analysis.
As shown in figure 4, there were 2.7- or 1.8- fold
increases in DNA fragmentation in 80 nM ATRA or 5
μM zoledronic acid exposed OVCAR-3 cells, respec-
t i v e l y ,a sc o m p a r e dt ou n t r e ated controls, while the
combination of both resulted in 7 fold increase in DNA
fragmentation (p < 0.05). In MDAH-2774 cells, there
were 2.0- or 1.9- fold increase in DNA fragmentation in
40 nM ATRA or 5 μM zoledronic acid exposed MDAH-
2774 cells respectively, as compared to untreated con-
trols, while the combination of both resulted in 6.2 fold
increase in DNA fragmentation (figure 4) (p < 0.05).
These doses were chosen to put in the figure, since they
represent the most demonstrative synergistic dose-
dependent effect of the combination.
b) Caspase 3/7 enzyme activity
Caspases are commonly referred to as hangmans of
apoptosis. The activation of caspases is an evidence of
apoptosis in cells. In order to confirm the apoptotic
effects of combination treatment in OVCAR-3 cells, we
examined the changes in caspase 3/7 enzyme activity.
The results revealed that there was a dose dependent
increase in caspase 3/7 enzyme activity in ATRA or
zoledronic acid in OVCAR-3 cells (data not shown).
Specifically, OVCAR-3 cells exposed to 80 nM ATRA or
5 μM zoledronic acid showed 2.8- or 1.7- fold increases
Figure 3 Synergistic cytotoxic effects of ATRA and zoledronic
acid (ZA) combination on viability of OVCAR-3 and MDAH-
2774 cells at 72 h in culture (p < 0.05).
Figure 4 Apoptotic effects of ATRA and zoledronic acid (ZA)
alone or in combination in OVCAR-3 and MDAH-2774 cells
through DNA fragmentation analyses (p < 0.05).
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to untreated controls, while their combination resulted
in 6.6- fold increases in caspase-3/7 enzyme activity
(figure 5) (p < 0.05). MDAH-2774 cells exposed to 40
nM ATRA or 5 μM zoledronic acid showed 3.1- or 2.2-
fold increases in caspase 3/7 enzyme activity, respec-
t i v e l y ,a sc o m p a r e dt ou n t r e ated controls, while their
combination resulted in 6.1- fold increases in caspase-
3/7 enzyme activity (figure 5) (p < 0.05).
Oligoarray and RT-PCR analyses of apoptosis-related genes
in OVCAR-3 cells by the combination treatment
We used apoptosis specific oligoarray to examine the
changes in expression levels of mRNAs of the apoptosis
related genes in response to ATRA and zoledronic acid
treatment in OVCAR-3 cells as compared to untreated
controls. Based on the IC50 results of each agent in
OVCAR-3 and MDAH-2774 cells, OVCAR-3 cancer
cells were found to be more chemorefractory. Thus, we
have chosen OVCAR-3 cell line to study the mechanis-
tic rationale of apoptosis with this combination. For this
experiment, we have applied the doses of 80 nM ATRA
and 5 μM zoledronic acid for oligoarray experiments.
These doses were chosen because they are much more
less than the IC50 doses of each agent and weak indu-
cers of apoptosis in OVCAR-3 cells, and thus letting the
oligoarray results not to be shaded by strong apoptotic
effect. Three repeated experiments were carried out and
the results showed that there were 6.8-, 4.9- and 4.8-
fold increase in TNFRSF 1A, 10B and TNFRSF 1A-asso-
ciated death domain (TRADD) mRNA levels in
OVCAR-3 cells when treated with combination of
ATRA and zoledronic acid, as compared to any agent
alone (table 2) (p < 0.05). Moreover, proapoptotic mem-
bers of Bcl-2 family (i.e BNIP3) were also shown to be
induced whereas the antiapoptotic members of the same
family (i.e BCL2L1, BCL2L12, BCL2L13) were inhibited
by the treatment.
In contrary, mRNA levels of lymphotoxin beta recep-
tor (LTBR), myeloid cell leukemia-1 (MCL-1) and
BCL2-associated athanogene 3 (BAG3) were reduced by
the combination treatment by 4.9-, 3.3- and 3.1- fold
decrease, respectively, as compared to each of the single
agent (table 2) (p < 0.05). The genes mentioned above
are responsible for resistance to apoptosis in many types
of human cancer cells, thus the reduction of mRNA
levels of these genes point out that the synergistic com-
bination treatment is effective on inducing apoptosis in
OVCAR-3 cells.
The results of the oligoarray data were validated by
quantitative real-time RT-PCR, using three genes relevant
to apoptosis: I) Proapoptotic genes: TNFRS1A and
TRADD which are both the key genes that start the apop-
totic cascade when induced in cancer cells, II) Antiapopto-
tic genes: MCL-1 and LTBR which both have versatile
roles in regulation of apoptosis and cell cycle progression.
For all these genes, the levels of expression observed
by quantitative RT-PCR highly correlated with the data
obtained by oligoarray analysis. TNFRS1A and TRADD
are found to be upregulated by 8.3- and 3.5- fold by
combination treatment, whereas MCL-1 and LTBR were
downregulated by 4.9- and 3.6- fold, respectively, as
compared to any agent alone (table 3) (p < 0.05).
Discussion
D e s p i t et or e s p o n s et os o m ee f f e c t i v et h e r a p e u t i c
approaches, decreased ability to undergo apoptosis by
malignant evolution of cancer cells is one of the main
problems of daily oncology practice [23]. Selective stra-
tegies to manipulate cancer cells towards apoptosis
rather than normal cells in the tissue are emerging as
Figure 5 Percentage changes in caspase 3/7 enzyme activity in
ATRA and zoledronic acid combination or any agent alone
exposed OVCAR-3 and MDAH-2774 cells (p < 0.05).
Table 2 Fold changes in apoptosis related genes by
OligoArray in OVCAR-3 cells
Fold Change in OVCAR-3 cells
Gene Symbol ATRA
(80 nM)
Zoledronic Acid
(5 μM)
Combination
BCL2L-1 (BCL-xL) -1.8 -2.1 -4.0
BCL2L12 -1.3 -1.5 -3.1
BCL2L13 -1.3 -2.6 -7.0
BNIP3 +1.9 +2.4 +3.9
TNFRSF1A +1.5 +3.6 +6.8
TNFRSF10B +1.6 +3.4 +4.9
TRADD +1.3 +1.2 +4.8
CASP4 +1.2 +1.4 +3.2
MCL-1 -2.2 -1.6 -3.3
BAG3 -1.0 -1.0 -3.1
LTBR -1.4 +2.5 -4.9
*p < 0.05
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agents that are non-toxic for healthy cells are promising
agents of future cancer treatment.
Our preliminary preclinical data demonstrated that the
combination of ATRA and zoledronic acid has synergis-
tic cytotoxic effect in OVCAR-3 and MDAH-2774 ovar-
ian cancer cells as compared to any agent alone. Since
ATRA is known to potentiate the cytotoxicity of some
conventional chemotherapeutics, this enhancement
effect has also observed in combination with zoledronic
acid for ovarian cancer cells in our experiments. In addi-
tion, it was also shown that this combination induces
apoptosis synergistically in ovarian cancer cells through
activation of caspases and induction of DNA fragmenta-
tion. We have also shown that the combination of
ATRA and zoledronic acid significantly alters the levels
of some important apoptosis-related molecules in
OVCAR-3 cells, both by oligoarray and RT-PCR
analyses.
By oligoarray analysis, we have shown that the mRNA
levels of TNFRSF genes are induced by the exposure of
the both agents. In the cancer cell, the death-signaling
pathway begins from the interaction of TNFRs with
their specific ligands and this pathway subsequently
initiates apoptosis via activation of caspases and down-
stream of protein cascade leading to cell death [24,25].
Among these receptors, TNFRSF 1A is one of the most
popular receptor since its ligand, tumor necrosis factor-
a (TNF-a), takes roles in wide range biological activities
associated with apoptosis/cell survival in many type of
cells [26]. After TNF-a recruits to its receptor, an inter-
action between cytoplasmic death domain of TNFR 1A
and the adaptor molecule TNFRSF 1A-associated death
domain protein (TRADD) takes place. We have shown
that mRNA levels of TNFRS 1A, 10B and TRADD were
increased by the combination treatment with ATRA and
zoledronic acid, suggesting the cell was under strong
apoptotic stimuli. Besides, caspase 4 mRNA levels were
also up-regulated by the same combination. In the lit-
erature, there is a body of evidence showing that expo-
sure to ATRA results in the upregulation of cell surface
expression of TNFRs in some type of cancer cells [27].
Thus, exposure of cancer cells with ATRA and zoledro-
nic acid combination results in strong apoptotic stimuli
through TNFRs.
The Bcl-2 family proteins are central regulators of
apoptosis because they integrate diverse survival and
death signals that are generated outside and inside the
cell [28,29]. The combination treatment in our study
resulted downregulation of some important Bcl-2 antia-
poptotic members (Bcl-2 L1, Bcl-2 L12, Bcl-2 L13)
whereas an induction in proapoptotic family member
(the Bcl-2/adenovirus E1B-19K interacting protein
BNIP3) was observed. Besides, there was a downregula-
tion of mRNA levels of BAG3 with ATRA and zoledro-
nic acid combination. BAG-3 (Bis) has also been
reported to associate with the anti-apoptotic protein
Bcl-2 [30]. Functional analysis revealed that BAG-3 itself
exerts only weak anti-apoptotic activity, but acts syner-
gistically with Bcl-2 in preventing Bax-induced and
FasL/Fas-mediated apoptosis
mRNA levels of MCL-1 and LTBR genes were also
reduced by the combination treatment. The MCL-1
gene was discovered incidentally as an induction gene in
myeloblastic leukemia cell differentiation about a decade
ago and proved to be a member of the emerging Bcl-2
gene family [31]. LTBR is also a very good example of
two-way functioning molecules. LTBR is a member of
TNFRSF that regulate cell survival or death through
activation of nuclear factor kappa B (NF-kappaB). In
some studies, it was clearly shown that by binding
LTBR with some specific or oligo-sense antibodies
resulted in decreased tumor growth and increased apop-
tosis in tumor cells [32-34].
Our oligo array results were also verified with RT-
PCR assay, and the results highly correlated with each
other. Of these genes, TNFRSF1A and TRADD were
found to be upregulated since they work as the trigger
molecules of the apoptotic cascade in cancer cells
whereas antiapoptotic genes MCL-1 and LTBR were
found to be downregulated.
Conclusions
Retinoids are widely investigated as the enhancers of
cytotoxic agents in cancer treatment. Since they do not
have any significant toxic side effect, they represent good
candidates for combination treatment. Zoledronic acid,
far beyond its effect on bone turn over, has presented
some novel antitumoral activity even in the adjuvant
treatment of cancer. So, in conclusion, these findings
provide basic molecular information for further investiga-
tion on the mechanisms by which ATRA and zoledronic
acid exert their pleiotropic effects in ovarian cancer cells.
However, our study has some important limitations; first
we do not yet provide in vivo results of our combination
Table 3 OligoArray and RT-PCR comparison of fold
changes in apoptosis related genes
OVCAR-3 Cells
(80 nM ATRA+5 μM Zoledronic Acid)
OligoArray Analysis RT-PCR Analysis
TNFRSF1A +6.8 +8.3
TRADD +4.8 +3.5
MCL-1 -3.3 -4.9
LTBR -4.9 -3.6
Comparing fold changes in apoptosis related genes in OVCAR-3 cells by
OligoArray and RT-PCR analyses after each drug exposure. Both results
showed high correlation with each other (p < 0.05).
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Page 7 of 9treatment, which will certainly be very helpful to support
our data. Latter, our experiments have been tested only
in ovarian cancer cells, and should further be validated in
normal ovarian cells. Further in-depth investigations
should be done to confirm the efficacy of this potentially
new treatment for ovarian cancer.
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